CN114544822B - Application of reagent for detecting lysophosphatidylcholine (22:0) in blood plasma in preparation of depression detection kit - Google Patents
Application of reagent for detecting lysophosphatidylcholine (22:0) in blood plasma in preparation of depression detection kit Download PDFInfo
- Publication number
- CN114544822B CN114544822B CN202011334992.3A CN202011334992A CN114544822B CN 114544822 B CN114544822 B CN 114544822B CN 202011334992 A CN202011334992 A CN 202011334992A CN 114544822 B CN114544822 B CN 114544822B
- Authority
- CN
- China
- Prior art keywords
- depression
- lysophosphatidylcholine
- reagent
- application
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- UIINDYGXBHJQHX-GDLZYMKVSA-N 1-behenoyl-2-hydroxy-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C UIINDYGXBHJQHX-GDLZYMKVSA-N 0.000 title claims abstract description 23
- 238000001514 detection method Methods 0.000 title claims abstract description 19
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims description 5
- 210000002381 plasma Anatomy 0.000 title abstract description 24
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 10
- 235000019253 formic acid Nutrition 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 4
- 238000004811 liquid chromatography Methods 0.000 claims description 3
- 230000000994 depressogenic effect Effects 0.000 abstract description 4
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 230000004069 differentiation Effects 0.000 abstract 1
- 239000003550 marker Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 description 1
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000002117 illicit drug Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The application discloses an application of a reagent for detecting lysophosphatidylcholine (22:0) in blood plasma in preparing a depression detection kit, and belongs to the field of depression detection. The use of the present application is based on the fact that there is a difference in lysophosphatidylcholine (22:0) in plasma between depressed patients and normal persons, which is sufficient for accurate differentiation between depressed patients and normal persons. The application also discloses a detection kit based on the principle. The kit can realize quantifiable objective detection and has the advantages of sensitivity, rapidness and high reliability.
Description
Technical Field
The application belongs to the field of depression detection, and particularly relates to application of a reagent for detecting lysophosphatidylcholine (22:0) in blood plasma in preparation of a depression detection kit.
Background
Depression is a major type of mood disorder, characterized by a significant and persistent depression in the mood. As one of the diseases with the highest disability rate in the world, the burden of depression patients on families, healthcare systems and society is enormous. It is estimated that up to 50% of 80 ten thousand suicide animals worldwide exist annually. Currently, the global depression patient population accumulates more than 3.5 hundred million people, and China has more than 5400 ten thousand people suffering from depression.
The depression has remarkable hereditary property, the hereditary rate reaches 30% -40%, and a plurality of hereditary factors are involved. It is also affected by a variety of non-genetic factors that increase the complexity of the pathogenesis of depression. The unclear pathogenesis causes that the diagnosis method for the disease is always remained on subjective observation levels such as a questionnaire scale, and lacks objective examination indexes, and meanwhile, the operation difficulty is high and the diagnosis period is long. Therefore, it is urgent to develop a sensitive, rapid, highly reliable diagnostic method or apparatus based on quantifiable objective indicators.
Lysophosphatidylcholine (LPC) is an intermediate product of lecithin metabolism in the body, and if the concentration is increased, it can solubilize erythrocyte membranes. Lecithin in plasma can be converted to lysolecithin under the catalysis of lecithin cholesterol acyltransferase. Lysophosphatidylcholine (22:0) is one of lysophosphatidylcholine. At present, no relationship between lysophosphatidylcholine (22:0) in blood and depression has been reported.
Disclosure of Invention
The application aims to solve the problems that: provides a new application of lysophosphatidylcholine (22:0) as a marker of depression.
The technical scheme of the application is as follows:
use of a reagent for detecting lysophosphatidylcholine (22:0) in plasma for the preparation of a depression detection kit.
Further, the reagent is a reagent for a liquid chromatography-mass spectrometry method.
Further, the reagent is a reagent for a liquid chromatography method.
Further, the kit comprises T 3 HSS chromatographic column, pure water dissolved 0.1% formic acid as mobile phase a and acetonitrile dissolved 0.1% formic acid as mobile phase B.
Further, the detection standard of the kit is as follows: when the plasma of the tested person is significantly lower than that of healthy people, the tested person is judged to be a high risk person of depression.
A depression detection kit, characterized in that: the kit comprises reagents for detecting lysophosphatidylcholine (22:0) in plasma.
Further, the reagent is a reagent for a liquid chromatography-mass spectrometry method.
Further, the reagent is a reagent for a liquid chromatography method.
Further, the kit comprises T 3 HSS chromatographic column, pure water dissolved 0.1% formic acid as mobile phase a and acetonitrile dissolved 0.1% formic acid as mobile phase B.
Further, the detection standard of the kit is as follows: when the plasma of the tested person is significantly lower than that of healthy people, the tested person is judged to be a high risk person of depression.
The key point of the application is that it is determined that the level of human plasma lysophosphatidylcholine (22:0) is significantly related to depression, so that the risk of depression can be judged by detecting the level of human plasma lysophosphatidylcholine (22:0), and as for the specific detection of lysophosphatidylcholine (22:0), various means disclosed in the prior art can be adopted, and the detection of the embodiment of the application by using the liquid chromatography-mass spectrometry method is not meant to be limited to the method.
The application provides a novel depression detection marker and a novel depression detection kit, which can realize quantitative objective detection of depression and have the advantages of sensitivity, rapidness and high reliability.
It should be apparent that, in light of the foregoing, various modifications, substitutions and alterations can be made herein without departing from the spirit and scope of the application as defined by the appended claims.
The above-described aspects of the present application will be described in further detail below with reference to specific embodiments in the form of examples. It should not be understood that the scope of the above subject matter of the present application is limited to the following examples only. All techniques implemented based on the above description of the application are within the scope of the application.
Drawings
Fig. 1: relative amounts of lysophosphatidylcholine (22:0) in depressed and normal control plasma; CON, control; MDD, depression.
Detailed Description
Example 1 Depression detection kit and method of use thereof
1. Composition of the kit
Standard pure liquid containing 12mg/ml plasma metabolism marker, 1C 8 BEH column (1.7 μm, 2.1X100 mm) and 1T 3 HSS column (1.8 μm, 2.1X100 mm), pure water dissolved 0.1% formic acid, acetonitrile dissolved 0.1% formic acid. Wherein the plasma metabolic marker is lysophosphatidylcholine (22:0).
2. Application method
(a) Injecting the prepared plasma sample into a chromatographic column through an automatic sampler, and separating metabolites in positive and negative ionization modes respectively under the specific chromatographic conditions that: mobile phase A is 0.1% formic acid dissolved in pure water; mobile phase B was 0.1% formic acid dissolved in acetonitrile. For the positive mode, the gradient initially starts at 10% b, increases linearly to 40% b in 4 minutes after 1 minute, then increases to 100% b in 12 minutes and remains for 5 minutes, then returns to the initial ratio balance for about 3 minutes. In negative mode, the gradient starts at 100% a, increases linearly to 40% b after 1 minute, then increases to 100% b in 9 minutes, and remains for 4 minutes, then returns to the initial ratio equilibrium for about 4 minutes. The column temperature was 55 ℃.
(b) The separated metabolites were imported into a liquid chromatograph-mass spectrometer Shimadzu LC (30 AD) -MS (TQ 8050) to acquire dynamic multi-reaction monitoring (MRM) data for validation, and the main parameters of the mass spectrum were the same as positive and negative modes: the flow rate of the heating gas is 10L/min; the flow rate of the dry gas flow is 10L/min; the flow rate of the atomized air flow is 3L/min; the DL temperature was 250 ℃; the temperature of the heating block is 400 ℃; the interface heater temperature was 300 ℃.
(c) Based on the relative concentrations of lysophosphatidylcholine (22:0), the subject was assessed for depression. Relative concentrations < 0.0027 determine a high risk of depression.
The kit is designed based on the plasma metabolic marker provided by the application, and can be used for accurately diagnosing and accurately evaluating patients suffering from depression.
To demonstrate the effectiveness of lysophosphatidylcholine (22:0) in assessing depression, the present application provides the following experimental examples.
Experimental example 1 comparison of plasma lysophosphatidylcholine (22:0) concentration between depressed patients and normal controls
50 cases of clinical depression and normal control were collected, each of which was prepared as 5ml plasma samples. 100 samples were taken from a first hospital affiliated with Chongqing university, subjects in the depression group excluded from past or present suffering from other neurological or psychiatric disorders, alcoholism or dependence on illicit drug use or pregnancy, and were diagnosed as depression by a first hospital affiliated with Chongqing university using the DSM-IV-TR standard, and a Hamiltonian depression scale was implemented to assess the severity of depression. Normal control subjects were excluded from any past or present neurological disease, I-axis or II-axis disease or systemic medical disease. The study protocol fully met the ethical criteria of human trials and was approved by the ethical committee of Chongqing medical university, subjects were known prior to the test and were given written consent.
The plasma sample was tested for plasma lysophosphatidylcholine (22:0) concentration by the kit and method of example 1, as shown in FIG. 1, and the plasma lysophosphatidylcholine (22:0) concentration was much lower in patients with depression than in controls (p<0.001 FDR of 0.0001, log 2 |FC|＝-0.9965。
Note that: FDR refers to the false discovery rate, FDR of 0 indicates that the expected value of the ratio of the number of false rejections (rejecting true (original) hypotheses) to the number of all rejected original hypotheses is 0.0001. The method comprises the steps of carrying out a first treatment on the surface of the FC refers to fold change.
The results of the experimental examples show that the plasma lysophosphatidylcholine (22:0) of the patients with depression is obviously lower than that of normal people, and the plasma lysophosphatidylcholine (22:0) concentration can be used for distinguishing the patients with depression from the normal people.
In conclusion, the kit provided by the application can be used for rapid auxiliary diagnosis of depression and has a good application prospect.
Claims (3)
1. Use of a reagent for detecting lysophosphatidylcholine (22:0) in plasma for the preparation of a depression detection kit, characterized in that:
the reagent is used for a liquid chromatography-mass spectrometry method;
or the reagent is a reagent for a liquid chromatography method.
2. The use according to claim 1, characterized in that: the kit comprises T 3 HSS chromatographic column, pure water dissolved 0.1% formic acid as mobile phase a and acetonitrile dissolved 0.1% formic acid as mobile phase B.
3. The use according to claim 1, characterized in that: the detection standard of the kit is as follows: when the plasma of the tested person is significantly lower than that of healthy people, the tested person is judged to be a high risk person of depression.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011334992.3A CN114544822B (en) | 2020-11-24 | 2020-11-24 | Application of reagent for detecting lysophosphatidylcholine (22:0) in blood plasma in preparation of depression detection kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011334992.3A CN114544822B (en) | 2020-11-24 | 2020-11-24 | Application of reagent for detecting lysophosphatidylcholine (22:0) in blood plasma in preparation of depression detection kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114544822A CN114544822A (en) | 2022-05-27 |
| CN114544822B true CN114544822B (en) | 2023-10-24 |
Family
ID=81659213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011334992.3A Active CN114544822B (en) | 2020-11-24 | 2020-11-24 | Application of reagent for detecting lysophosphatidylcholine (22:0) in blood plasma in preparation of depression detection kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114544822B (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102565267A (en) * | 2012-01-06 | 2012-07-11 | 北京师范大学 | Kit for screening colorectal cancer |
| CN102788883A (en) * | 2012-08-30 | 2012-11-21 | 重庆医科大学 | Kit for detecting depression |
| WO2014150329A1 (en) * | 2013-03-14 | 2014-09-25 | University Of Georgia Research Foundation, Inc. | Lipid biomarkers of addiction and relapse risk |
| JP2016045112A (en) * | 2014-08-25 | 2016-04-04 | 株式会社 レオロジー機能食品研究所 | Ether phospholipid quantifying method |
| CN108885219A (en) * | 2016-02-04 | 2018-11-23 | 梅坦诺米克斯有限公司 | Device and method for identifying heart failure and pulmonary disease in subject |
| CN109164194A (en) * | 2018-11-02 | 2019-01-08 | 质谱生物科技有限公司 | The detection method and its kit of lysophosphatidyl cholines in dried blood spot |
| CN109444433A (en) * | 2018-12-18 | 2019-03-08 | 深圳先进技术研究院 | D-Ser is preparing application and Diagnosis of Depression kit in Diagnosis of Depression kit as marker |
| CN110286191A (en) * | 2019-06-27 | 2019-09-27 | 山西大学 | Metabolic indicator object detecting method and application in a kind of biological sample |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8637321B2 (en) * | 2005-10-24 | 2014-01-28 | Duke University | Lipidomics approaches for central nervous system disorders |
| MA45276A (en) * | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE |
| US11903974B2 (en) * | 2015-11-30 | 2024-02-20 | Flagship Pioneering Innovations V, Inc. | Methods and compositions relating to chondrisomes from cultured cells |
| CA3030219A1 (en) * | 2016-07-07 | 2018-01-11 | Berg Llc | Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancer |
-
2020
- 2020-11-24 CN CN202011334992.3A patent/CN114544822B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102565267A (en) * | 2012-01-06 | 2012-07-11 | 北京师范大学 | Kit for screening colorectal cancer |
| CN102788883A (en) * | 2012-08-30 | 2012-11-21 | 重庆医科大学 | Kit for detecting depression |
| WO2014150329A1 (en) * | 2013-03-14 | 2014-09-25 | University Of Georgia Research Foundation, Inc. | Lipid biomarkers of addiction and relapse risk |
| JP2016045112A (en) * | 2014-08-25 | 2016-04-04 | 株式会社 レオロジー機能食品研究所 | Ether phospholipid quantifying method |
| CN108885219A (en) * | 2016-02-04 | 2018-11-23 | 梅坦诺米克斯有限公司 | Device and method for identifying heart failure and pulmonary disease in subject |
| CN109164194A (en) * | 2018-11-02 | 2019-01-08 | 质谱生物科技有限公司 | The detection method and its kit of lysophosphatidyl cholines in dried blood spot |
| CN109444433A (en) * | 2018-12-18 | 2019-03-08 | 深圳先进技术研究院 | D-Ser is preparing application and Diagnosis of Depression kit in Diagnosis of Depression kit as marker |
| CN110286191A (en) * | 2019-06-27 | 2019-09-27 | 山西大学 | Metabolic indicator object detecting method and application in a kind of biological sample |
Non-Patent Citations (6)
| Title |
|---|
| "Discovery and Validation of Plasma Biomarkers for Major Depressive Disorder Classification Based on Liquid Chromatography−Mass Spectrometry";Liu XY. et al;《Journal of Proteome Research》;第14卷(第5期);第2322-2330页 * |
| "Metabolic fingerprint of Gestational Diabetes Mellitus";Dudzik, D et al;《JOURNAL OF PROTEOMICS》;第103卷;第57-71页 * |
| "Plasma lipidomics reveals potential lipid markers of major depressive disorder";Liu, XY et al;《ANALYTICAL AND BIOANALYTICAL CHEMISTRY》;第408卷(第23期);第6497-6507页 * |
| "基于代谢组学的百合知母汤治疗抑郁症的作用研究";刘职瑞等;《第三军医大学学报》;第41卷(第20期);第1917-1925页 * |
| "抑郁症患者代谢组与肠道菌群结构特征分析及Bacopaside Ⅰ抗抑郁作用的机制研究";祖先鹏;《中国优秀博士学位论文全文数据库医药卫生科技》(第1期);第1-244页 * |
| "高原缺氧代谢组学研究进展";赵明亮等;《中草药》;第49卷(第4期);第948-954页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114544822A (en) | 2022-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111289736A (en) | Slow obstructive pulmonary early diagnosis marker based on metabonomics and application thereof | |
| WO2022206264A1 (en) | Method for diagnosing and treating white matter lesion and application | |
| Liang et al. | Metabolomics of alcoholic liver disease: a clinical discovery study | |
| Laila et al. | Role of proteomics in the discovery of autism biomarkers | |
| CN112083111A (en) | Non-invasive diagnosis marker for chronic drug-induced liver injury related cirrhosis and application thereof | |
| US9529002B2 (en) | Biomarkers for prediction, diagnosis, and monitoring of Alzheimer's disease | |
| CN114544790B (en) | Application of reagent for detecting lysophosphatidylethanolamine (22:5) in blood plasma in preparation of depression detection kit | |
| CN113447599B (en) | Biomarker for diagnosing cerebral infarction of patient with leukoencephalopathy and application of biomarker | |
| CN113624868A (en) | Biomarker combination for predicting or evaluating cognitive function of bipolar affective disorder patient and application thereof | |
| CN114544822B (en) | Application of reagent for detecting lysophosphatidylcholine (22:0) in blood plasma in preparation of depression detection kit | |
| CN114544821B (en) | Application of reagent for detecting phosphatidylethanolamine (36:4) in blood plasma in preparation of depression detection kit | |
| CN114544826B (en) | Application of reagent for detecting histidine in blood plasma in preparation of depression detection kit | |
| CN114019061B (en) | Biomarker for Parkinson disease detection and application thereof | |
| CN114047263A (en) | Application of metabolic marker in preparation of detection reagent or detection object for diagnosing AIS (automatic identification system) and kit | |
| CN114544825A (en) | Application of reagent for detecting lysophosphatidylcholine (16:1) in plasma in preparation of depression detection kit | |
| CN113624870A (en) | Biomarker combination for predicting PANSS scale score of schizophrenia patient and application thereof | |
| US20140322734A1 (en) | Biomarkers for prediction, diagnosis, and monitoring of parkinson's disease | |
| CN113552228A (en) | Combined markers for diagnosing childhood bronchiolitis and application and detection kit thereof | |
| Ko et al. | Breath gas analysis for a potential diagnostic method of neurodegenerative diseases | |
| RU2818128C2 (en) | Method for diagnosing mental disorders by blood lipids | |
| CN114047281B (en) | Combination of biomarkers for parkinson's disease and uses thereof | |
| CN112599237B (en) | Biomarker and application thereof in cerebral infarction diagnosis | |
| CN116469541B (en) | Depression marker, application thereof in depression prognosis and evaluation device | |
| CN115326958B (en) | Marker composition for assisting in predicting or diagnosing obesity-associated hyperlipidemia children | |
| WO2024109767A1 (en) | Fecal metabolite-based alzheimer's disease marker and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |